Cancer Clinical Trial
Official title:
Improving Young Adult Cancer Survivors' Mental Health With an eHealth Group Intervention
The purpose of this study is to determine the feasibility of recruiting young adult cancer survivors from across the nation and to explore the impact of an eHealth group intervention on mental health and stress biomarkers in this population.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | May 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 39 Years |
Eligibility | Inclusion Criteria: 1. Aged 18-39 years at the time of participation 2. Diagnosed with any invasive cancer between 15-39 years old 3. Finished curative cancer treatment 1 month to 5 years prior to enrollment (except maintenance therapy such as ongoing hormone therapy) 4. Currently experiencing at least mild symptoms of depression or anxiety (i.e., score =1 on the Patient Health Questionnaire-485) 5. Able to speak and read English so all group attendees can communicate in a shared language. 6. Able and willing to give informed consent. 7. Access to internet or cellular connectivity with sufficient bandwidth to participate in videoconferences Exclusion Criteria: 1) Documented or observable psychiatric or neurological disorders that could interfere with study participation (e.g., psychosis, active substance abuse) |
Country | Name | City | State |
---|---|---|---|
United States | University of Arizona Cancer Center | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
University of Arizona |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nationwide recruitment of young adult cancer survivors | Nationwide recruitment will be considered feasible if =40% of eligible survivors enroll in the study. | At the end of the one-year study period | |
Primary | Change in depression symptoms from baseline to immediately after the intervention | Participants will complete the Patient Health Questionnaire-9. Given the sample size, we will focus on effect sizes rather than statistical significance. | Baseline and immediately after the intervention. | |
Primary | Change in anxiety symptoms from baseline to immediately after the intervention | Participants will complete the Generalized Anxiety Disorder-7. Given the sample size, we will focus on effect sizes rather than statistical significance. | Baseline and immediately after the intervention. | |
Secondary | Change in trend and relative values of time and frequency domain heart rate variability metrics from pre- to post-intervention. | Participants will wear a wearable sensor (e.g., Oura ring) for at least 1 week. | Baseline and the final week of the intervention | |
Secondary | Change in health-related quality of life from baseline to immediately after the intervention | Participants will complete the 27-item Functional Assessment of Cancer Therapy - General. Scores range from 0 to 108, with higher scores reflecting better quality of life. | Baseline and immediately after the intervention | |
Secondary | Change in cancer-related distress from baseline to immediately after the intervention | Participants will complete the 22-item Impact of Event Scale-Revised. Scores range from 0 to 88, with higher scores indicating greater cancer-related distress. | Baseline and immediately after the intervention | |
Secondary | Change in stress management self-efficacy skills from baseline to immediately after the intervention | Participants will complete subscales from the Measure of Current Status. Subscale scores range from 0 to 8, 0 to 12, or 0 to 20 depending on the subscale. Higher scores indicate more of the construct being assessed. | Baseline and immediately after the intervention | |
Secondary | Change in coping from baseline to immediately after the intervention | Participants will complete the Brief Coping Orientation to Problems Experienced scale, which yields 14 two-item subscales. Subscale scores range from 2 to 8, with higher scores indicating greater usage of the coping strategy being assessed. | Baseline and immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|